Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17135228rdf:typepubmed:Citationlld:pubmed
pubmed-article:17135228lifeskim:mentionsumls-concept:C1522565lld:lifeskim
pubmed-article:17135228lifeskim:mentionsumls-concept:C0020542lld:lifeskim
pubmed-article:17135228lifeskim:mentionsumls-concept:C0277785lld:lifeskim
pubmed-article:17135228lifeskim:mentionsumls-concept:C0039155lld:lifeskim
pubmed-article:17135228lifeskim:mentionsumls-concept:C0754710lld:lifeskim
pubmed-article:17135228pubmed:issue4lld:pubmed
pubmed-article:17135228pubmed:dateCreated2007-4-2lld:pubmed
pubmed-article:17135228pubmed:abstractTextRight ventricular systolic dysfunction (RVSD) at baseline (pre-treatment) predicts early death in patients with pulmonary hypertension (PH). However, RVSD can only be detected reliably by prohibitively invasive or expensive techniques. N-terminal B-type natriuretic peptide concentration ([NT-proBNP]) correlates with RV function in PH; however, an [NT-proBNP] threshold that indicates RVSD in individual patients has not previously been determined. Twenty-five patients with PH (pulmonary arterial hypertension (n = 19) or chronic thromboembolic PH (n = 6)) underwent cardiovascular magnetic resonance (CMR) imaging and NT-proBNP measurement at baseline. [NT-proBNP] was correlated against RV dimensions and ejection fraction (RVEF) measured directly by CMR imaging. The ability of NT-proBNP to detect RVSD (defined as a CMR-derived RVEF >2 SDS below control values) was tested and predictors of [NT-proBNP] identified. [NT-proBNP] correlated negatively with RVEF. RVSD was present in nine out of 25 patients. An [NT-proBNP] threshold of 1,685 pg.mL(-1) was sensitive (100%) and specific (94%) in detecting RVSD. RVEF and RV mass index independently predicted [NT-proBNP]. In pulmonary hypertension, a baseline N-terminal B-type natriuretic peptide concentration of >1,685 ng.L(-1) suggests right ventricular systolic dysfunction, and thus an increased risk of early death. N-terminal B-type natriuretic peptide could prove useful as an objective, noninvasive means of identifying patients with pulmonary hypertension who have right ventricular systolic dysfunction at presentation.lld:pubmed
pubmed-article:17135228pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17135228pubmed:languageenglld:pubmed
pubmed-article:17135228pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17135228pubmed:citationSubsetIMlld:pubmed
pubmed-article:17135228pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17135228pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17135228pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17135228pubmed:statusMEDLINElld:pubmed
pubmed-article:17135228pubmed:monthAprlld:pubmed
pubmed-article:17135228pubmed:issn0903-1936lld:pubmed
pubmed-article:17135228pubmed:authorpubmed-author:MortonJ JJJlld:pubmed
pubmed-article:17135228pubmed:authorpubmed-author:DargieH JHJlld:pubmed
pubmed-article:17135228pubmed:authorpubmed-author:PeacockA JAJlld:pubmed
pubmed-article:17135228pubmed:authorpubmed-author:FosterJ EJElld:pubmed
pubmed-article:17135228pubmed:authorpubmed-author:MartinT NTNlld:pubmed
pubmed-article:17135228pubmed:authorpubmed-author:GroenningB...lld:pubmed
pubmed-article:17135228pubmed:authorpubmed-author:MarkP BPBlld:pubmed
pubmed-article:17135228pubmed:authorpubmed-author:BlythK GKGlld:pubmed
pubmed-article:17135228pubmed:authorpubmed-author:SteedmanTTlld:pubmed
pubmed-article:17135228pubmed:issnTypePrintlld:pubmed
pubmed-article:17135228pubmed:volume29lld:pubmed
pubmed-article:17135228pubmed:ownerNLMlld:pubmed
pubmed-article:17135228pubmed:authorsCompleteYlld:pubmed
pubmed-article:17135228pubmed:pagination737-44lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:meshHeadingpubmed-meshheading:17135228...lld:pubmed
pubmed-article:17135228pubmed:year2007lld:pubmed
pubmed-article:17135228pubmed:articleTitleNT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension.lld:pubmed
pubmed-article:17135228pubmed:affiliationScottish Pulmonary Vascular Unit, University of Glasgow, Glasgow G11 6NT, UK.lld:pubmed
pubmed-article:17135228pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17135228lld:pubmed